Attached files

file filename
8-K - 8-K - CHART INDUSTRIES INCd431445d8k.htm

Exhibit 99.1

Chart Industries Reports 2012 Third Quarter Results

Cleveland, Ohio – November 1, 2012—Chart Industries, Inc. (NASDAQ: GTLS), a leading independent global manufacturer of highly engineered equipment used in the production, storage and end-use of hydrocarbon and industrial gases, today reported results for the third quarter ended September 30, 2012. Highlights include:

 

  Record sales of $254 million, up 20% over third quarter 2011

 

  Announces brazed aluminum heat exchanger capacity expansion

 

  Completes AirSep acquisition

Net income for the third quarter of 2012 was $18.5 million, or $0.61 per diluted share. This compares with $17.5 million, or $0.59 per diluted share, for the third quarter of 2011. Third quarter 2012 earnings would have been $0.66 per diluted share excluding $2.0 million, or $0.05 per diluted share, of BioMedical acquisition-related costs largely associated with the AirSep acquisition. Third quarter 2011 earnings would have been $0.62 per diluted share excluding $1.2 million, or $0.03 per diluted share, of acquisition-related restructuring costs.

Net sales for the third quarter of 2012 increased 20% to a record $254.2 million from $211.3 million in the comparable period a year ago. Gross profit for the third quarter of 2012 was $78.0 million, or 30.7% of sales, versus $66.6 million, or 31.5% of sales, in the comparable quarter of 2011.

“We closed the AirSep acquisition in August and our results include one month of AirSep activity,” stated Sam Thomas, Chart’s Chairman, President and Chief Executive Officer. “This acquisition strengthens our BioMedical oxygen concentrator business and complements the expansion projects currently underway to address capacity constraints within our rapidly growing energy business.”

Mr. Thomas continued, “We are also embarking on an expansion of our production capacity for brazed aluminum heat exchangers (“BAHX”) in response to significant demand for high pressure BAHX. Worldwide demand for BAHX remains strong due to strength in natural gas processing, olefin production, air separation, and LNG applications, and we plan to have this additional capacity on line by 2014 to meet customer expectations.”

Backlog at September 30, 2012 was $639.8 million, down slightly from the June 30, 2012 backlog of $648.1 million. Orders for the third quarter of 2012 were $233.4 million compared with second quarter 2012 orders of $228.0 million. The third quarter of 2012 included $11.6 million in AirSep orders. Excluding AirSep, orders declined slightly due to continued weakness in Europe, which is impacting operations in this region, particularly in our BioMedical respiratory business.

Selling, general and administrative (“SG&A”) expenses for the third quarter of 2012 increased $8.0 million compared with the same period in 2011 to $42.2 million, or 16.6% of sales, which was up as a percentage of sales from 16.2% in the prior year quarter. The increase is largely due to acquisitions, as well as employee-related costs as we continue to expand our resources to capture natural gas related growth opportunities.

Interest expense was $4.0 million for the third quarter of 2012, which included $2.3 million of non-cash accretion expense associated with the Company’s Convertible Notes. Therefore, cash


interest was $1.7 million. Interest expense was higher in the prior year quarter by $2.4 million as the Convertible Notes and the now repaid 9-1/8% Senior Subordinated Notes were both outstanding for approximately two months during the third quarter of 2011.

Income tax expense was $8.4 million for the third quarter of 2012 and represented an effective tax rate of 30.7% compared with the effective tax rate of 28.9% in the prior year quarter. The 2012 third quarter effective tax rate was higher due to an increase in domestic earnings, which are taxed at a higher rate than our foreign earnings.

Cash and cash equivalents were $105.8 million at September 30, 2012, approximately $148.9 million lower than balances at June 30, 2012. We used $182.5 million of cash to close the AirSep acquisition in August 2012.

SEGMENT HIGHLIGHTS

Energy & Chemical (“E&C”) segment sales increased approximately 44% to $83.0 million for the third quarter of 2012 compared with $57.8 million for the same quarter in the prior year. Gross margins declined to 29.2% in the quarter compared with 33.1% in the same quarter of 2011. The third quarter of 2011 included the sale of equipment that was previously written-off, which favorably impacted margins about 3% in the prior year quarter. Excluding this item, margins were down about 1% due to project mix.

Distribution & Storage (“D&S”) segment sales improved approximately 17% to $117.8 million for the third quarter of 2012 compared with $100.9 million for the same quarter in the prior year. The increase in sales was largely due to improved volume, particularly for LNG applications. The acquisition of GOFA in August 2011 also contributed to the improvement. D&S gross profit margin was 30.3% in the quarter compared with 28.2% a year ago. Higher volume and improved capacity utilization led to the margin improvement.

BioMedical segment sales improved approximately 2% to $53.5 million for the third quarter of 2012 compared with $52.6 million for the same quarter in the prior year. AirSep, which was acquired in August 2012, added $8.6 million in sales. Excluding AirSep, respiratory sales declined due to continued weakness in Europe, including the weak euro, and phase-in of Medicare competitive bidding in the U.S. BioMedical gross profit margin was 33.8% in the quarter compared with 36.2% a year ago. Margin declined due to lower volume, unfavorable product mix, the weak euro, and AirSep related restructuring charges.

OUTLOOK

We continue to experience significant growth in our natural gas related businesses; however, continued weakness in our BioMedical respiratory business in Europe and the U.S. plus softening in our D&S industrial gas business globally is impacting results more than anticipated. Considering the collective impact of year-to-date results, current order backlog, the addition of AirSep and current business expectations, the Company is lowering its earnings guidance for 2012. We are tightening our 2012 sales guidance range to $980 million to $1 billion, which is within the range previously forecasted. Full year earnings per share for 2012 are now expected to be in the range of $2.35 to $2.45 per diluted share, on approximately 30 million weighted average shares outstanding. Included in our 2012 earnings estimates are approximately $0.10 per diluted share of anticipated restructuring charges for recent acquisitions. Excluding these charges, earnings would be expected to fall in a range of $2.45 to $2.55 per share.


FORWARD-LOOKING STATEMENTS

Certain statements made in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning the Company’s plans, objectives, future orders, revenues, earnings or performance, liquidity and cash flow, capital expenditures, business trends, and other information that is not historical in nature. Forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “expects,” “anticipates,” “believes,” “projects,” “forecasts,” “outlook,” “guidance,” “continue,” or the negative of such terms or comparable terminology. Forward-looking statements contained in this news release or in other statements made by the Company are made based on management’s expectations and beliefs concerning future events impacting the Company and are subject to uncertainties and factors relating to the Company’s operations and business environment, all of which are difficult to predict and many of which are beyond the Company’s control, that could cause the Company’s actual results to differ materially from those matters expressed or implied by forward-looking statements. These factors and uncertainties include, among others, the following: the cyclicality of the markets that the Company serves and the vulnerability of those markets to economic downturns; a delay, significant reduction in or loss of purchases by large customers; fluctuations in energy prices; changes in government energy policy or the failure of expected changes in policy to materialize; the potential for negative developments in the natural gas industry related to hydraulic fracturing; competition; economic downturns and deteriorating financial conditions; our ability to manage our fixed-price contract exposure; our reliance on key suppliers and potential supplier failures or defects; the modification or cancellation of orders in our backlog; the Company’s ability to successfully manage its costs and growth, including its ability to successfully manage operational expansions and the challenges and uncertainties associated with efforts to acquire and integrate new product lines or businesses; the Company’s ability to successfully integrate AirSep’s business, and achieve anticipated revenue, earnings and accretion related to AirSep; the Company’s ability to obtain third-party approvals necessary for planned operational expansions; changes in government healthcare regulations and reimbursement and funding policies; general economic, political, business and market risks associated with the Company’s international operations and transactions; fluctuations in foreign currency exchange and interest rates; financial distress of third parties; loss of key employees and deterioration of employee or labor relations; the pricing and availability of raw materials; the regulation of our products by the U.S. Food & Drug Administration and other governmental authorities; potential future impairment of the Company’s significant goodwill and other intangibles; the cost of compliance with environmental, health and safety laws; additional liabilities related to taxes; the impact of severe weather; litigation and disputes involving the Company, including product liability, contract, warranty, employment and environmental claims; and volatility and fluctuations in the price of the Company’s stock. For a discussion of these and additional factors that could cause actual results to differ from those described in the forward-looking statements, see the Company’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which should be reviewed carefully. The Company undertakes no obligation to update or revise any forward-looking statement.

Chart is a leading independent global manufacturer of highly engineered equipment used in the production, storage and end-use of hydrocarbon and industrial gases. The majority of Chart’s products are used throughout the liquid gas supply chain for purification, liquefaction, distribution, storage and end-use applications, the largest portion of which are energy-related. Chart has domestic operations located across the United States and an international presence in Asia, Australia and Europe. For more information, visit: http://www.chart-ind.com.


Use of Non-GAAP Financial Information:

To supplement the unaudited condensed consolidated financial statements presented in accordance with U.S. GAAP in this news release, certain non-GAAP financial measures as defined by the SEC rules are used. The non-GAAP measures included in this news release have been reconciled to the comparable GAAP measures within an accompanying table, shown on the last page of this news release.

As previously announced, the Company will discuss its third quarter 2012 results on a conference call on Thursday, November 1, 2012 at 10:30 a.m. ET. Participants may join the conference call by dialing (877) 317-6789 in the U.S. or (412) 317-6789 from outside the U.S. A live webcast presentation will also be accessible at 10:30 a.m. ET at http://www.chart-ind.com. Please log-in or dial-in at least five minutes prior to the start time.

A taped replay of the conference call will be archived on the Company’s website, www.chart-ind.com, approximately one hour after the call concludes. You may also listen to a taped replay of the conference call by dialing (877) 344-7529 in the U.S. or (412) 317-0088 outside the U.S. and entering Conference Number 10019829. The telephone replay will be available beginning approximately one hour after the end of the call until 9:00 a.m. ET, Friday, November 9, 2012.

For more information, click here:

http://www.b2i.us/irpass.asp?BzID=1444&to=ea&Nav=0&S=0&L=1

 

Contact:      
Michael F. Biehl                                     or            Kenneth J. Webster
Executive Vice President, Chief Financial Officer and Treasurer       Vice President, Chief Accounting Officer and Controller
216-626-1216       216-626-1216
michael.biehl@chart-ind.com       ken.webster@chart-ind.com


CHART INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

(Dollars and shares in thousands, except per share amounts)

 

     Three Months Ended September 30,
    Nine Months Ended September 30,  
     2012      2011     2012      2011  

Sales

   $ 254,249       $ 211,311      $ 710,294       $ 574,950   

Cost of sales

     176,237         144,680        490,596         393,503   
  

 

 

    

 

 

   

 

 

    

 

 

 

Gross profit

     78,012         66,631        219,698         181,447   

Selling, general and administrative expenses

     42,170         34,127        117,522         105,326   

Amortization expense

     3,810         3,342        10,130         9,947   

Loss on disposal of assets

     —           119        —           1,335   

Impairment of intangible assets

     —           —          3,070         —     
  

 

 

    

 

 

   

 

 

    

 

 

 
     45,980         37,588        130,722         116,608   
  

 

 

    

 

 

   

 

 

    

 

 

 

Operating income (1)

     32,032         29,043        88,976         64,839   

Other expenses (income):

          

Interest expense and financing costs amortization, net

     4,332         6,806        12,860         15,452   

Foreign currency losses (gains)

     461         (2,390     1,879         (2,533
  

 

 

    

 

 

   

 

 

    

 

 

 
     4,793         4,416        14,739         12,919   
  

 

 

    

 

 

   

 

 

    

 

 

 

Income before income taxes

     27,239         24,627        74,237         51,920   

Income tax expense

     8,354         7,122        23,064         15,992   
  

 

 

    

 

 

   

 

 

    

 

 

 

Net income

     18,885         17,505        51,173         35,928   

Noncontrolling interest, net of tax

     369         (35     638         267   
  

 

 

    

 

 

   

 

 

    

 

 

 

Net income attributable to Chart Industries, Inc.

   $ 18,516       $ 17,540      $ 50,535       $ 35,661   
  

 

 

    

 

 

   

 

 

    

 

 

 

Net income attributable to Chart Industries, Inc. per common
share – basic

   $ 0.62       $ 0.60      $ 1.70       $ 1.23   
  

 

 

    

 

 

   

 

 

    

 

 

 

Net income attributable to Chart Industries, Inc. per common
share – diluted

   $ 0.61       $ 0.59      $ 1.68       $ 1.19   
  

 

 

    

 

 

   

 

 

    

 

 

 

Weighted average number of common shares outstanding – basic

     29,839         29,288        29,743         29,088   
  

 

 

    

 

 

   

 

 

    

 

 

 

Weighted average number of common shares outstanding – diluted

     30,243         29,966        30,168         29,871   
  

 

 

    

 

 

   

 

 

    

 

 

 

 

(1) 

Includes depreciation expense of $4,406 and $3,679 for the three months ended September 30, 2012 and 2011, respectively, and $12,644 and $10,463 for the nine months ended September 30, 2012 and 2011, respectively.


CHART INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(Dollars in thousands)

 

     Three Months Ended September 30,
    Nine Months Ended September 30,  
     2012     2011     2012     2011  

Net Cash Provided By Operating Activities

   $ 19,398      $ 51,822      $ 14,473      $ 37,043   

Investing Activities

        

Capital expenditures

     (12,149     (4,728     (28,951     (15,161

Proceeds from sale of assets

     2,040               2,040          

Acquisition of businesses, net of cash acquired

     (182,450     (36,070     (182,450     (37,680

Other investing activities

     (359            (359     388   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net Cash Used In Investing Activities

     (192,918     (40,798     (209,720     (52,453
  

 

 

   

 

 

   

 

 

   

 

 

 

Financing Activities

        

Proceeds from long-term debt

                   21,375          

Borrowings on revolving credit facilities

     18,387               18,387          

Principal payments on long-term debt

     (937     (1,625     (3,500     (4,875

Proceeds from issuance of convertible notes

            250,000               250,000   

Proceeds from issuance of warrants

            48,848               48,848   

Payment for call options related to convertible notes

            (66,486            (66,486

Payment of deferred financing costs

     13        (6,993     (1,445     (7,340

Proceeds from exercise of options

     1,481        216        3,324        5,101   

Tax benefit from exercise of stock options

     1,579               7,934        6,984   

Payment of contingent consideration

     (1,300     (1,300     (1,300     (1,300

Common stock repurchases

     (46            (4,537     (1,090
  

 

 

   

 

 

   

 

 

   

 

 

 

Net Cash Provided By Financing Activities

     19,177        222,660        40,238        229,842   

Effect of exchange rate changes on cash

     5,409        (4,014     3,923        2,501   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net (decrease) increase in cash and cash equivalents

     (148,934     229,670        (151,086     216,933   

Cash and cash equivalents at beginning of period

     254,709        152,375        256,861        165,112   
  

 

 

   

 

 

   

 

 

   

 

 

 

Cash And Cash Equivalents At End of Period

   $ 105,775      $ 382,045      $ 105,775      $ 382,045   
  

 

 

   

 

 

   

 

 

   

 

 

 


CHART INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Dollars in thousands)

 

     September 30,
2012
     December 31,
2011
 
     (Unaudited)         

ASSETS

     

Cash and cash equivalents

   $ 105,775       $ 256,861   

Other current assets

     466,096         340,768   

Property, plant and equipment, net

     158,672         137,301   

Goodwill

     387,242         288,770   

Identifiable intangible assets, net

     194,631         140,553   

Other assets, net

     10,820         10,222   
  

 

 

    

 

 

 

TOTAL ASSETS

   $ 1,323,236       $ 1,174,475   
  

 

 

    

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

     

Current liabilities

   $ 294,346       $ 265,493   

Long-term debt

     250,640         223,224   

Other long-term liabilities

     99,268         72,207   

Shareholders’ equity

     678,982         613,551   
  

 

 

    

 

 

 

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

   $ 1,323,236       $ 1,174,475   
  

 

 

    

 

 

 


CHART INDUSTRIES, INC. AND SUBSIDIARIES

OPERATING SEGMENTS (UNAUDITED)

(Dollars in thousands)

 

     Three Months Ended September 30,     Nine Months Ended September 30,  
     2012     2011     2012     2011  

Sales

        

Energy & Chemicals

   $ 82,968      $ 57,777      $ 228,921      $ 149,414   

Distribution & Storage

     117,752        100,911        336,278        275,966   

BioMedical

     53,529        52,623        145,095        149,570   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total

   $ 254,249      $ 211,311      $ 710,294      $ 574,950   
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross Profit

        

Energy & Chemicals

   $ 24,255      $ 19,121      $ 69,264      $ 45,180   

Distribution & Storage

     35,678        28,455        95,968        78,898   

BioMedical

     18,079        19,055        54,466        57,369   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total

   $ 78,012      $ 66,631      $ 219,698      $ 181,447   
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross Profit Margin

        

Energy & Chemicals

     29.2     33.1     30.3     30.2

Distribution & Storage

     30.3     28.2     28.5     28.6

BioMedical

     33.8     36.2     37.5     38.4

Total

     30.7     31.5     30.9     31.6

Operating Income (Loss)

        

Energy & Chemicals

   $ 17,057      $ 12,584      $ 44,785      $ 21,941   

Distribution & Storage

     19,948        16,109        54,447        44,731   

BioMedical

     7,051        8,548        25,498        24,218   

Corporate

     (12,024     (8,198     (35,754     (26,051
  

 

 

   

 

 

   

 

 

   

 

 

 

Total

   $ 32,032      $ 29,043      $ 88,976      $ 64,839   
  

 

 

   

 

 

   

 

 

   

 

 

 


CHART INDUSTRIES, INC. AND SUBSIDIARIES

ORDERS AND BACKLOG (UNAUDITED)

(Dollars in thousands)

 

     Three Months Ended  
     September 30,
2012
     June 30,
2012
 

Orders

     

Energy & Chemicals

   $ 56,435       $ 58,119   

Distribution & Storage

     120,388         121,376   

BioMedical

     56,598         48,459   
  

 

 

    

 

 

 

Total

   $ 233,421       $ 227,954   
  

 

 

    

 

 

 

Backlog

     

Energy & Chemicals

   $ 397,741       $ 424,005   

Distribution & Storage

     214,377         211,963   

BioMedical

     27,708         12,173   
  

 

 

    

 

 

 

Total

   $ 639,826       $ 648,141   
  

 

 

    

 

 

 


CHART INDUSTRIES, INC. AND SUBSIDIARIES

RECONCILIATION OF EARNINGS PER DILUTED SHARE TO ADJUSTED EARNINGS PER DILUTED SHARE

(UNAUDITED)

 

     Three Months Ended  
     September 30,
2012
     September 30,
2011
 

Earnings per diluted share

   $ .61       $ .59   

Inventory write-up to fair value

     .02         .01   

Severance

     .02         .01   

Acquisition expenses/other

     .01         .01   
  

 

 

    

 

 

 

Adjusted earnings per diluted share

   $ .66       $ .62